Starting November 11, South Korea will initiate a targeted COVID-19 vaccination program for high-risk infants and children aged 6 months to 11 years. The Korea Disease Control and Prevention Agency (KDCA) announced the rollout on November 5, providing a protected pathway for immunocompromised children and those residing in infection-vulnerable facilities.
Clinical Requirements for Pediatric Vaccination
- Eligibility: Only high-risk groups, including immunocompromised children and residents of infection-vulnerable facilities, are currently prioritized for this vaccination cycle.
- Documentation: Parents must present medical certificates or physician’s opinion letters at the vaccination site to verify the child’s high-risk status.
- Post-Vaccination Protocol: Patients are required to remain at the medical facility for 20 to 30 minutes following the injection to monitor for adverse reactions.
Emergency Introduction for Pediatric Populations
The KDCA confirmed that this vaccination campaign is a result of an emergency introduction of vaccines, as there are currently no COVID-19 vaccines officially licensed or approved for children under 12 years of age in South Korea. By deploying these specific formulations, health authorities aim to mitigate the risk of severe disease progression in children with existing health vulnerabilities.
According to reports from Yonhap News Agency and Hankyung, the national immunization program is scheduled to run through April 30 of next year. Parents can identify participating medical institutions via the official KDCA “Immunization Assistant” website. The agency emphasizes that children who have not yet completed their primary vaccination series must receive their initial one or two doses, while those who have already completed the primary series are eligible for a single annual booster, or two doses annually for those classified as immunocompromised.
Comparison of Vaccination Protocols and Eligibility
| Category | Requirement |
|---|---|
| Target Demographic | High-risk infants/children (6 months–11 years) |
| Program Duration | November 11, 2026 – April 30, 2027 |
| Primary Series | Required for those not yet vaccinated (1-2 doses) |
| Booster Frequency | 1 dose annually (2 doses for immunocompromised) |
| Verification | Medical certificate or physician opinion required |
Commissioner Lim Outlines Clinical Oversight Measures
KDCA Commissioner Lim Seung-kwan highlighted the necessity of these measures to ensure that children at high risk for severe COVID-19 complications can get through the winter season safely. The clinical guidance remains consistent: after the administration of the vaccine, the child should rest sufficiently and be observed for signs of adverse reactions.
The urgency of this program is emphasized by national vaccination trends. As of 6:00 p.m. on November 4, approximately 3.91 million individuals—or 34.2% of the population aged 65 and older—had participated in the 2026–2027 seasonal COVID-19 vaccination campaign. The KDCA maintains that both elderly citizens and immunocompromised pediatric patients constitute the primary high-risk groups requiring consistent immunization to manage public health outcomes.
